Safety, efficacy, and phar- macodynarnics of the investigational agent ortonel (TAK-700)in meta- static castration resistant prostate cancer (mCRPC):updated data from a phase 1 / II study

查看全文 作　　者：Agus DB; Stadler WM; Shevrin DH; 出　　处：《J Clin Oncol》索引2012年第30卷第5期,共0页